Evaluating patient reported outcomes in routine practice of patients with rheumatoid arthritis treated with biological disease modifying anti rheumatic drugs (b-DMARDs)
Crossref DOI link:
Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY
Boone, Niels W.
van der Kuy, Paul-Hugo
Landewé, Robert B. M.
Funding for this research was provided by:
Pfizer Netherlands (WI188344)
unspecified valid from 2015-08-28